🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 67% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
Other Combinations Product Type
67% Evidence Coverage

Supplement Facts — Evidence Check

100 mcg (125% DV)
✅ Within RDA (0.8× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.1mg
Calcium
25 mg (3% DV)
20 mg (2% DV)
📊 Market median: 99.0mg (503 products) 📚 12 studies (Tier A: 0, B: 3)
RDA 700mg This product: 20mg UL 4000mg

Other Ingredients

Microcrystalline Cellulose Croscarmellose Sodium Stearic Acid Acacia Magnesium Stearate Sucrose Aqueous Film Coating

Label Claims — Verification

All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: Take 1 tablet daily, as a dietary supplement, or as directed by a physician.

Best if used by date on bottle.

⚠️ Warnings & Precautions

Warning: If you are taking any medications or are pregnant or nursing do not use prior to consulting a physician.

For your protection, this container has an outer safety seal. (Do not accept if missing or broken.)

Keep out of reach of children

Additional Information

Circulation support

Store in a dry, cool place.

C-104006

Product Details

UPC / SKU 7 03308 94023 7
DSLD Entry Date 2017-09-21
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 78500
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →